Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting
March 28, 2017 13:38 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3...
Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
January 06, 2017 09:00 ET
|
Adamas Pharmaceuticals, Inc.
-- PDUFA Action Date Set for August 24, 2017 -- -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson’s Disease -- EMERYVILLE, Calif.,...
Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
January 03, 2017 16:52 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in...